This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marso, S. P. Articles by Hiatt, W. R. Search for Related Content PubMed PubMed Citation Articles by Marso, S. P. Articles by Hiatt, W. R.

Peripheral Arterial Disease in Patients With Diabetes

Steven P. Marso, MD, FACC^_*,_* and William R. Hiatt, MD

^_* Mid America Heart Institute, University of Missouri-Kansas City, Saint Luke's Hospital, Kansas City, Missouri
Divisions of Geriatrics and Cardiology, Section of Vascular Medicine, University of Colorado Health Sciences Center and the Colorado Prevention Center, Denver, Colorado

View larger version (13K): [in a new window]   Figure 1 Typical protocol for the diagnosis of peripheral arterial disease in patients with diabetes. Reprinted with permission from N Engl J Med 2001;344:1608–21. Copyright © 2001 Massachusetts Medical Society. All rights reserved. ABI = ankle-brachial index; PAD = peripheral arterial disease; PVR = pulse-volume recording; UDS = ultrasonic duplex scanning.

View larger version (16K): [in a new window]   Figure 2 Relative-risk reduction and 95% confidence interval by disease subgroup in the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial. MI = myocardial infarction; PAD = peripheral arterial disease. Reprinted with permission from Elsevier (Lancet 1996;348:1329–39).

View larger version (13K): [in a new window]   Figure 3 The mean maximal walking distance increase from baseline in patients with peripheral arterial disease after 24 weeks of treatment with placebo (n = 239), pentoxifylline 400 mg three times daily (n = 232), or cilostazol 100 mg twice daily (n = 227). *p < 0.001 vs. pentoxifylline (84).